查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1668193

急性偏頭痛藥物市場 - 全球產業規模、佔有率、趨勢、機會和預測，按治療、給藥途徑、配銷通路、地區和競爭進行細分，2020-2030 年預測

Acute Migraine Drugs Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Treatment, By Route of Administration, By Distribution Channel, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球急性偏頭痛藥物市場價值為 23.5 億美元，預計在預測期內將持續成長，到 2030 年的年複合成長率(CAGR) 為 4.80%。 該市場是製藥行業中的關鍵部分，專注於滿足偏頭痛患者的緊急醫療需求 偏頭痛是一種令人嘔吐、令人衰弱和嘔吐系統的神經疾病，伴隨著其嚴重性影響。它包括一系列旨在緩解偏頭痛發作期間的症狀並減少其復發的藥物解決方案。

市場概況
預測期 2026-2030
2024 年市場規模 23.5 億美元
2030 年市場規模 31.2 億美元
2025-2030 年複合年成長率 4.80％
成長最快的領域 預防
最大的市場 北美洲

主要市場促進因素：

主要市場挑戰：

主要市場趨勢：

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：顧客之聲

第 5 章：急性偏頭痛藥物市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依治療（預防、緩解疼痛）
    • 依給藥途徑（口服、注射、鼻腔噴霧、其他）
    • 按配銷通路（醫院藥房、零售藥房、網路藥房）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第 6 章：北美急性偏頭痛藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 加拿大
    • 墨西哥

第 7 章：歐洲急性偏頭痛藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 英國
    • 義大利
    • 法國
    • 西班牙

第 8 章：亞太地區急性偏頭痛藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章：南美洲急性偏頭痛藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲急性偏頭痛藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 合併與收購

第 13 章：全球急性偏頭痛藥物市場：SWOT 分析

第 14 章：競爭格局

  • Endo International PLC
  • AbbVie Inc.
  • Impax Laboratories LLC
  • Glaxo Smith Kline PLC
  • Astellas Pharma Inc
  • Amgen Inc
  • Bayer AG
  • AstraZeneca PLC
  • Dr. Reddy's Laboratories Ltd
  • Eli Lilly and Company
  • Pfizer Inc

第 15 章：策略建議

第16章 關於出版商,免責事項

簡介目錄
Product Code: 17586

The global Acute Migraine Drugs Market was valued at USD 2.35 billion in 2024 and is projected to experience consistent growth during the forecast period, with a compound annual growth rate (CAGR) of 4.80% through 2030. This market represents a critical segment within the pharmaceutical industry, focusing on addressing the immediate medical needs of individuals suffering from migraines-a debilitating neurological disorder characterized by severe headaches, often accompanied by nausea, vomiting, and light sensitivity. It includes a range of pharmaceutical solutions designed to alleviate symptoms during migraine episodes and reduce their recurrence.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 2.35 Billion
Market Size 2030USD 3.12 Billion
CAGR 2025-20304.80%
Fastest Growing SegmentPreventive
Largest MarketNorth America

Key Market Drivers:

1. Increasing Global Prevalence of Migraine: The rising global prevalence of migraine is a major driver of growth in the Global Acute Migraine Drugs Market. Between 1990 and 2021, the global migraine burden increased significantly, with prevalence rising by 58.15%, from 732.56 million to 1.16 billion cases. The incidence rate also climbed by 42.06%, signaling a notable surge in newly diagnosed cases. Furthermore, Disability-Adjusted Life Years (DALYs) linked to migraines increased by 58.27%, highlighting the growing health and economic burden of the condition worldwide. This surge points to an expanding market opportunity for acute migraine treatments as pharmaceutical companies and healthcare providers address the increasing demand for effective solutions. As the number of migraine sufferers grows, the demand for fast-acting and specialized treatments rises correspondingly. Migraines are among the most common neurological disorders, affecting millions globally, and are recognized as one of the leading causes of disability, according to health organizations such as the World Health Organization (WHO) and the Global Burden of Disease Study. The rising number of patients seeking treatment is directly contributing to the expanding market for acute migraine drugs, with both prescription and over-the-counter (OTC) medications seeing increased sales and revenue potential. The growing prevalence is not limited to specific demographics, as it spans across various age groups and regions, offering new opportunities for pharmaceutical companies.

Key Market Challenges:

1. Regulatory Barriers and Stringent Approval Processes: Regulatory approvals are essential for ensuring patient safety but can also present challenges in the development and commercialization of new migraine drugs. Regulatory agencies like the FDA and EMA impose strict criteria, requiring extensive clinical trials, meticulous data collection, and significant time and resource investment. The extended approval timelines can delay the market introduction of innovative migraine treatments, limiting patient access to potentially improved options and impacting pharmaceutical companies' revenue streams. To address this, companies must adopt proactive engagement strategies with regulatory bodies, such as early communication, well-designed clinical trials, and thorough data collection efforts to expedite the approval process.

Key Market Trends:

1. Personalized Medicine and Targeted Therapies: Personalized medicine is transforming the migraine treatment landscape by tailoring therapies to individual patient profiles, taking into account genetic, lifestyle, and clinical factors. Targeted therapies address the underlying mechanisms of migraine attacks, improving treatment efficacy and minimizing adverse effects, thereby enhancing patient outcomes. This trend meets growing patient demand for more effective solutions and drives innovation and market expansion. Pharmaceutical companies are investing in research to identify biomarkers and genetic factors linked to migraine susceptibility, leading to the development of drugs with precise mechanisms of action that offer personalized treatment options for patients.

Key Market Players:

  • Endo International PLC
  • AbbVie Inc.
  • Impax Laboratories LLC
  • GlaxoSmithKline PLC
  • Astellas Pharma Inc.
  • Amgen Inc.
  • Bayer AG
  • AstraZeneca PLC
  • Dr. Reddy's Laboratories Ltd
  • Eli Lilly and Company
  • Pfizer Inc.

Report Scope: The Global Acute Migraine Drugs Market has been segmented as follows, along with detailed industry trends:

By Treatment:

  • Preventive
  • Pain Relieving

By Route of Administration:

  • Oral
  • Injectable
  • Nasal Sprays
  • Other

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America (United States, Canada, Mexico)
  • Europe (France, United Kingdom, Italy, Germany, Spain)
  • Asia-Pacific (China, India, Japan, Australia, South Korea)
  • South America (Brazil, Argentina, Colombia)
  • Middle East & Africa (South Africa, Saudi Arabia, UAE)

Competitive Landscape: In-depth analysis of major companies within the Global Acute Migraine Drugs Market.

Customization Options Available: TechSci Research offers tailored solutions for the Global Acute Migraine Drugs market report based on specific company needs.

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Acute Migraine Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment (Preventive, Pain Relieving)
    • 5.2.2. By Route of Administration (Oral, Injectable, Nasal Sprays, Others)
    • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map

6. North America Acute Migraine Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment
    • 6.2.2. By Route of Administration
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Acute Migraine Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Acute Migraine Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Acute Migraine Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By Distribution Channel

7. Europe Acute Migraine Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment
    • 7.2.2. By Route of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Acute Migraine Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. United Kingdom Acute Migraine Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. Italy Acute Migraine Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Treatment
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. France Acute Migraine Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment
        • 7.3.4.2.2. By Route of Administration
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Acute Migraine Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment
        • 7.3.5.2.2. By Route of Administration
        • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Acute Migraine Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Acute Migraine Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Acute Migraine Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Acute Migraine Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Acute Migraine Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment
        • 8.3.4.2.2. By Route of Administration
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Acute Migraine Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment
        • 8.3.5.2.2. By Route of Administration
        • 8.3.5.2.3. By Distribution Channel

9. South America Acute Migraine Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment
    • 9.2.2. By Route of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Acute Migraine Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Argentina Acute Migraine Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. Colombia Acute Migraine Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Acute Migraine Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment
    • 10.2.2. By Route of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Acute Migraine Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Saudi Arabia Acute Migraine Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. UAE Acute Migraine Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Acute Migraine Drugs Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Endo International PLC
    • 14.1.1. Business Overview
    • 14.1.2. Product & Service Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Financials (If Listed)
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. AbbVie Inc.
  • 14.3. Impax Laboratories LLC
  • 14.4. Glaxo Smith Kline PLC
  • 14.5. Astellas Pharma Inc
  • 14.6. Amgen Inc
  • 14.7. Bayer AG
  • 14.8. AstraZeneca PLC
  • 14.9. Dr. Reddy's Laboratories Ltd
  • 14.10.Eli Lilly and Company
  • 14.11.Pfizer Inc

15. Strategic Recommendations

16. About Us & Disclaimer